# hepatocellular carcinoma (HCC) - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 5
- Task type: PROGNOSIS
- Tissue / sample source: liver tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: be503ca72a7bcd2f0eb88c8049c4935f5ef704fb40bd5170c65ca64b33a1d716
- Response HTTP status: 200
- Prompt tokens: 27120
- Completion tokens: 9635
- Reasoning tokens: 0
- Total tokens: 36755
- API requests reported: 2
- Elapsed seconds: 76.993
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1376.986
- Question handoff seconds: 1390.502
- Final benchmark system: E2seq; file rank 3/5; original repeat 5; model vendor: DeepSeek

---
## 1. Overall biological interpretation

**Critical data-quality caveat.** This prognostic analysis displays a degenerate statistical profile: 97 of 100 selected genes are risk-associated with HR values at or near the machine limit (5.18e+21), 3 genes show protective HRs of ~1.93e-22, and all 100 genes carry P = 0 and FDR = 0. These values are not biologically plausible effect sizes; they indicate quasi-complete separation or near-zero variance events in the survival model, likely arising from extremely low expression counts, sparse detection, or zero-inflation in a small subgroup. The "direction-conflict" flags on Y_RNA (168 rows) and Metazoa_SRP (37 rows) further indicate unstable multi-row aggregation. **The HR values should therefore be interpreted as rank-ordering signals at best, not as quantitative hazard estimates.**

The gene list is dominated by olfactory receptor pseudogenes (OR5M13P, OR2M7, OR5T2, OR5M5P, OR5M6P, OR5M10, OR11J6P), ribosomal/RNA pseudogenes (RPL5P21, RNA5SP507, RNA5SP359), small nuclear/cytoplasmic RNA pseudogenes (RNU6-1134P, RNU6-71P, RNU7-180P, RNU7-159P, RN7SKP270, RN7SKP289), long intergenic non-coding RNAs (LINC00454, LINC01672, LINC02787, LINC02645, LINC00701, LINC01665, LINC02265, LINC00603, LINC02135), and unmapped/uncharacterized loci. Only a handful of protein-coding genes with known biology appear: CGB2, SLC1A6, IRS4, CRH, OTX2, FOXI1, FOXR2, TBC1D26, MIR182.

The dominant biological theme is therefore **not a coherent oncogenic program but a technical artifact pattern**: the risk-associated set consists largely of genes with tissue-inappropriate or near-absent expression in normal liver (olfactory receptors, placental/neuroendocrine markers), pseudogenes, and non-coding RNAs whose apparent "expression" likely reflects alignment artifacts, genomic contamination, or extreme sparsity. The few protein-coding genes (CGB2, SLC1A6, IRS4, CRH, OTX2, FOXI1, FOXR2) are biologically heterogeneous and do not converge on a single pathway, consistent with the GO/KEGG batch returning only scattered terms (L-aspartate transport, glucagon secretion regulation, type II diabetes mellitus, lipolysis regulation) driven largely by SLC1A6 and IRS4.

Interpretation strategy: treat the uploaded statistics as direct cohort evidence for *which genes separate survival groups*, but recognize that the separation is likely driven by technical or compositional factors rather than by shared biology. The few protein-coding genes with plausible HCC relevance (IRS4, CRH, MIR182, FOXR2) merit focused follow-up, while the pseudogene/OR/ncRNA majority should be treated as a quality-control signal.

## 2. Core biological programs

Given the degenerate statistics and heterogeneous gene composition, I identify only three defensible programs—one of which is a technical artifact pattern—rather than forcing five biological themes.

### Program 1: Technical artifact / low-complexity expression signal (dominant)
- **Direction:** risk-associated (97/100 genes)
- **Supporting genes:** OR5M13P, OR2M7, OR5T2, OR5M5P, OR5M6P, OR5M10, OR11J6P, RPL5P21, RNA5SP507, RNA5SP359, RNU6-1134P, RNU6-71P, RNU7-180P, RNU7-159P, RN7SKP270, RN7SKP289, RNU4-72P, RNU4-63P, Y_RNA, Metazoa_SRP, plus ~40 RP11-/AC-/LINC- loci and 8 UNMAPPED_ENSEMBL entries
- **Pathway:** Not applicable (no coherent GO/Reactome/KEGG term; olfactory transduction and RNA processing are irrelevant to HCC biology)
- **Why:** Olfactory receptors are not expressed in normal hepatocytes; pseudogenes and unmapped loci with HR=5.18e+21 and P=0 indicate near-zero counts in one survival group. The recurrence of OR genes in "GPCR signaling" and "sensory perception of smell" ontology modules is a byproduct of the gene identities, not evidence of an olfactory program in liver cancer.
- **Evidence strength:** Direct input statistics are extreme but biologically implausible. **This program is best interpreted as a data-quality warning, not a biological finding.**
- **Limitations:** Cannot distinguish alignment artifacts from genuine low-level ectopic expression without raw count inspection.

### Program 2: Neuroendocrine/placental marker ectopic expression
- **Direction:** risk-associated
- **Supporting genes:** CGB2 (HR=5.18e+21), CRH (HR=1.51e+06), OTX2 (HR=5.18e+21), SLC1A6 (HR=5.18e+21), IRS4 (HR=5.18e+21)
- **Pathway:** GO: regulation of glucagon secretion (GO:0070092); KEGG: type II diabetes mellitus, regulation of lipolysis in adipocytes (batch results)
- **Why:** CGB2 (chorionic gonadotropin beta), CRH (corticotropin-releasing hormone), and OTX2 (homeobox transcription factor) are normally expressed in placenta, hypothalamus, or developing brain—not adult liver. SLC1A6 is an excitatory amino-acid transporter with near-absent liver expression (GTEx: 0.007–0.018 TPM in non-brain tissues vs 2.6–7.5 TPM in brain). IRS4 is an insulin receptor substrate family member with roles in insulin/IGF signaling. Their co-selection as "risk" genes suggests ectopic or spuriously detected transcripts marking a distinct tumor subgroup, possibly neuroendocrine differentiation or a technical batch effect.
- **Evidence strength:** Direct statistics are extreme; external tissue evidence (GTEx) confirms these genes are not liver-expressed. **Supported hypothesis** that this represents ectopic expression or contamination, not a canonical HCC program.
- **Limitations:** The GO/KEGG terms (glucagon regulation, diabetes) are driven by SLC1A6 and IRS4 individually and do not represent a coherent network; no pathway enrichment statistic was computed.

### Program 3: Insulin/IGF signaling component (tentative, single-gene anchored)
- **Direction:** risk-associated
- **Supporting gene:** IRS4 (HR=5.18e+21)
- **Pathway:** KEGG: type II diabetes mellitus; regulation of lipolysis in adipocytes (batch results)
- **Why:** IRS4 is the only gene with a clear connection to a liver-relevant signaling axis (insulin/IGF-1 receptor signaling). IRS4 overexpression has been reported in some cancers, and insulin/IGF signaling is established in HCC progression. However, this program rests on a single gene and cannot be elevated to a core program.
- **Evidence strength:** **Insufficient evidence** for a program-level conclusion; single-gene support only.
- **Limitations:** No other insulin-pathway genes appear in the selected list; the KEGG term is a batch annotation, not an enrichment statistic.

## 3. Key genes and interaction modules

I limit this section to genes with identifiable biology and flag the interaction types explicitly. No direct physical interaction evidence is available from the supplied records for the HCC context.

### 1. IRS4 (risk-associated, HR=5.18e+21)
- **Role:** Insulin receptor substrate family member; potential node in insulin/IGF-1 signaling relevant to HCC proliferation and metabolism.
- **Interactions:** No direct interaction evidence in the supplied records. Pathway co-membership with insulin signaling (KEGG: type II diabetes mellitus) is annotation-based only.
- **Caveat:** HR is implausibly extreme; the association may be driven by low expression in one survival subgroup.

### 2. SLC1A6 (risk-associated, HR=5.18e+21)
- **Role:** Excitatory amino-acid transporter (EAAT4); normally brain-enriched (GTEx: 2.6–7.5 TPM in brain regions vs <0.02 TPM in liver-adjacent tissues). Its appearance in liver tumor data suggests ectopic expression, contamination, or a technical artifact.
- **Interactions:** STRING lists SLC1A6 interactions with SPTBN2, SLC1A1, ARHGEF11, KAT5, RORA (predicted/curated, confidence 0.90–0.95). These are protein-interaction database records, not direct physical interaction evidence in HCC. Pathway co-membership: glutamate neurotransmitter release cycle, SLC-mediated amino acid transport (Reactome).
- **Caveat:** The KAT5 link is shared with FOXR2 in the network evidence, but this is a database prediction, not a validated HCC interaction.

### 3. CRH (risk-associated, HR=1.51e+06)
- **Role:** Corticotropin-releasing hormone; neuroendocrine peptide. Not normally expressed in adult liver. May mark neuroendocrine differentiation or reflect non-hepatocyte contamination.
- **Interactions:** None reported in the supplied evidence.
- **Caveat:** HR is still extreme; the gene may be expressed in only a few samples.

### 4. CGB2 (risk-associated, HR=5.18e+21)
- **Role:** Chorionic gonadotropin beta subunit; placental marker. Ectopic expression in HCC has been reported in some studies as a paraneoplastic phenomenon.
- **Interactions:** STRING lists ABI2 and ACTL7A as predicted partners (confidence not shown); these are database predictions, not direct physical interactions.
- **Caveat:** Same extreme-HR caveat.

### 5. MIR182 (risk-associated, HR=5.18e+21)
- **Role:** microRNA with reported oncogenic roles in multiple cancers, including HCC; literature records support roles in ovarian carcinoma (PMID 22790015) and inflammatory bone resorption (PMID 31908034).
- **Interactions:** Regulatory interaction (miRNA–mRNA targeting) is its established mode of action, but no specific HCC targets are supplied in the current evidence.
- **Caveat:** The literature support is from other cancers; HCC-specific validation is absent.

### 6. FOXR2 (risk-associated, HR=5.18e+21)
- **Role:** Forkhead box R2 transcription factor; reported in some cancers as an oncogene.
- **Interactions:** STRING lists KAT5 as a predicted partner (shared with SLC1A6); database prediction only.
- **Caveat:** Single-gene support; no HCC-specific evidence in the supplied records.

### 7. Olfactory receptor cluster (OR2M7, OR5M10, OR5T2, OR5M13P, OR5M5P, OR5M6P, OR11J6P) — risk-associated
- **Role:** All near-identical HR=5.18e+21. These are not expressed in hepatocytes. The STRING records linking them to ARRB1, ARRB2, GNAL, GNB1, GNG13 reflect canonical olfactory GPCR signaling partners—pathway co-membership in olfactory transduction, not HCC biology.
- **Interaction type:** Pathway co-membership (GPCR signaling, olfactory transduction); no direct physical interaction evidence in HCC.

### 8. Pseudogene/ncRNA module (RPL5P21, RNA5SP507, RNU6-1134P, RNU7-180P, RN7SKP270, Y_RNA, Metazoa_SRP, plus ~40 RP11-/LINC- loci)
- **Role:** The single largest "module." These are non-coding or pseudogene loci with extreme HRs. Y_RNA shows direction-conflict across 168 rows; Metazoa_SRP across 37 rows—indicating unstable aggregation.
- **Interaction type:** None established. Co-occurrence in this list likely reflects a shared technical origin (alignment artifacts, genomic contamination, or low-count sparsity), not a biological interaction.

### 9. FOXI1 (risk-associated, HR=6.63e+13)
- **Role:** Forkhead box I1 transcription factor; expressed in kidney/ear, not normal liver. Ectopic expression may mark a differentiation state.
- **Interactions:** None reported.

### 10. OTX2 (risk-associated, HR=5.18e+21)
- **Role:** Orthodenticle homeobox 2; developmental transcription factor, not liver-expressed. Ectopic expression or artifact.
- **Interactions:** None reported.

## 4. Validation priorities

### Priority 1: Data-quality and composition check (Confounding or composition check)
- **Why:** The extreme HR values (5.18e+21) and the dominance of pseudogenes/ORs/ncRNAs indicate that the survival separation may be driven by technical artifacts, not biology.
- **Current evidence:** 97/100 genes risk-associated with P=0/FDR=0; direction-conflict flags on Y_RNA and Metazoa_SRP; GTEx shows near-absent liver expression for SLC1A6 and the OR cluster.
- **External evidence:** No independent-cohort statistic is available; external statistical validation was not performed.
- **Next step:** Inspect raw counts for the selected genes; verify alignment quality; compute tumor purity estimates (e.g., ESTIMATE, ABSOLUTE); test whether the risk group has lower overall read depth or higher contamination; re-run survival models after filtering low-expression genes (e.g., require >1 CPM in >20% of samples).
- **Conclusion status:** **Established evidence** that the statistics are degenerate; **exploratory hypothesis** that artifacts drive the separation.

### Priority 2: Ectopic expression / neuroendocrine differentiation marker panel (Mechanistic hypothesis)
- **Why:** CGB2, CRH, OTX2, SLC1A6, FOXI1 form a coherent "non-liver gene" set that could mark a neuroendocrine-like or poorly differentiated HCC subgroup.
- **Current evidence:** All risk-associated with extreme HRs; GTEx confirms non-liver expression.
- **External evidence:** Scattered literature on ectopic hCG (CGB) expression in HCC as a paraneoplastic marker; no systematic HCC cohort validation in the supplied records.
- **Next step:** Immunohistochemistry for chromogranin A, synaptophysin, and the candidate proteins on the same tumor cohort; RNA in situ hybridization to confirm tumor-cell origin vs stromal/contaminating cells.
- **Conclusion status:** **Supported hypothesis** that these are ectopically expressed; **exploratory hypothesis** that they define a clinically distinct HCC subgroup.

### Priority 3: IRS4–insulin/IGF signaling axis (Mechanistic hypothesis)
- **Why:** IRS4 is the only gene with clear relevance to a liver cancer-relevant signaling pathway (insulin/IGF-1), which is established in HCC.
- **Current evidence:** Single-gene risk association (HR=5.18e+21); KEGG batch annotation (type II diabetes mellitus).
- **External evidence:** Insulin/IGF signaling is well-established in HCC biology, but IRS4 specifically lacks HCC-specific validation in the supplied records.
- **Next step:** Measure IRS4 protein by IHC/WB in an independent HCC cohort; test IRS4 knockdown effects on HCC cell proliferation and insulin signaling in vitro.
- **Conclusion status:** **Exploratory hypothesis** (single-gene support; no independent cohort statistic).

### Priority 4: MIR182 as a prognostic biomarker (Biomarker)
- **Why:** MIR182 has published oncogenic roles in multiple cancers and is the only regulatory RNA with established biology in the list.
- **Current evidence:** Risk-associated (HR=5.18e+21); literature records in ovarian carcinoma (PMID 22790015) and inflammatory bone resorption (PMID 31908034) — not HCC-specific.
- **External evidence:** Literature support exists but is from other tumor types; HCC-specific validation is absent in the supplied records.
- **Next step:** qRT-PCR for miR-182 in an independent HCC cohort with survival data; correlate with known HCC targets (e.g., FOXO1, MITF if applicable).
- **Conclusion status:** **Exploratory hypothesis** (external literature from other cancers; no HCC cohort statistic).

### Priority 5: Pseudogene/OR cluster as contamination or batch marker (Confounding or composition check)
- **Why:** The ~60 pseudogene/OR/ncRNA loci with identical extreme HRs likely share a technical origin; validating this could prevent misinterpretation of the entire profile.
- **Current evidence:** Identical HR values (5.18e+21) across dozens of unrelated loci; direction-conflict flags on multi-row genes.
- **External evidence:** GTEx shows no liver expression for OR genes; no HCC literature supports olfactory receptor biology in this list.
- **Next step:** Check for cross-sample contamination (e.g., compare to RNA from other tissues in the same sequencing batch); verify whether these loci map to a single genomic region or repetitive element; test whether a single low-quality sample drives the association.
- **Conclusion status:** **Supported hypothesis** that this is technical; **exploratory hypothesis** regarding the specific mechanism.

## 5. Evidence grounding

| Claim | Direct input evidence | Pathway/ontology | Protein interaction | Disease association | Expression/tissue | Independent cohort |
|---|---|---|---|---|---|---|
| HR values are degenerate/implausible | Yes (extreme HRs, P=0) | — | — | — | — | No (not applicable) |
| Pseudogene/OR/ncRNA dominance is technical | Yes (97/100 risk, identical HRs) | Weak (olfactory transduction terms are artifacts of gene identity) | No | No | Yes (GTEx: no liver expression for ORs, SLC1A6) | Not performed |
| CGB2/CRH/OTX2/SLC1A6/FOXI1 are ectopic | Yes (risk-associated) | Partial (GO terms driven by single genes) | No | Scattered (ectopic hCG in HCC literature) | Yes (GTEx: non-liver expression) | Not performed |
| IRS4–insulin signaling is relevant to HCC | Yes (single gene, risk) | Partial (KEGG: type II diabetes) | No | Yes (insulin/IGF in HCC is established) | No | Not performed |
| MIR182 is oncogenic | Yes (risk) | No | No (regulatory by miRNA nature) | Yes (other cancers, PMID 22790015, 31908034) | No | Not performed |
| OR cluster interacts with ARRB1/GNB1 etc. | No | Yes (GPCR signaling co-membership) | Yes (STRING predictions) | No | No | Not performed |

**Independence note:** The GO/KEGG batch, STRING, Reactome, and GTEx records are external annotations. STRING interactions are largely predicted from orthology/co-occurrence and are not independent of the underlying literature. The KEGG terms (type II diabetes, lipolysis) derive from SLC1A6 and IRS4 annotations and do not constitute an enrichment test. **No independent-cohort statistic was supplied; external statistical validation was not performed.**

## 6. Limitations and alternative explanations

### 1. Quasi-complete separation / zero-inflation
The HR values at 5.18e+21 and 1.93e-22 with P=0 indicate that the survival model could not estimate a finite coefficient—likely because the "expressing" group is tiny or a single sample drives the separation. This makes the HRs non-interpretable as effect sizes. **Investigation:** examine the number of samples with nonzero counts per gene; use Firth's penalized likelihood or exact logistic regression.

### 2. Low tumor purity and non-hepatocyte contamination
Liver biopsies contain stroma, immune cells, biliary epithelium, and potentially blood. Genes like CGB2 (placenta), CRH (hypothalamus), and OTX2 (brain) are not expected in any of these either, making contamination from an external source (e.g., another tissue in the same sequencing lane) plausible. **Investigation:** estimate tumor purity; deconvolute cell types (CIBERSORTx, xCell); check for batch-level contamination.

### 3. Alignment artifacts and multi-mapping reads
Pseudogenes (RPL5P21, RNA5SP507), snRNA pseudogenes (RNU6-1134P), and unmapped ENSEMBL entries are classic sources of multi-mapping ambiguity. Identical HR values across dozens of these loci suggest a shared alignment or quantification artifact. **Investigation:** re-align with a splice-aware aligner; count only uniquely mapped reads; check mapping quality distributions.

### 4. Disease severity and treatment heterogeneity
OS as an endpoint conflates tumor biology with treatment response, liver function (Child-Pugh), and competing risks (liver failure, variceal bleeding). If the "risk" group has more advanced disease, any gene separating the groups may simply mark stage. **Investigation:** adjust for BCLC stage, AFP, Child-Pugh, and treatment in multivariate models.

### 5. Association-versus-causation ambiguity
Even for the biologically plausible candidates (IRS4, MIR182), a prognostic association does not establish a causal role. The extreme HRs preclude any quantitative causal interpretation. **Investigation:** functional experiments (knockdown/overexpression) in HCC models are required before any causal claim.

## Summary

The current prognostic profile is dominated by a degenerate statistical pattern—97/100 genes risk-associated with machine-limit HRs and P=0—that likely reflects technical artifacts (zero-inflation, alignment ambiguity, contamination) rather than a coherent HCC biology. The most defensible biological signals are (i) a possible ectopic/neuroendocrine-like expression module (CGB2, CRH, OTX2, SLC1A6, FOXI1) and (ii) a single-gene insulin-signaling candidate (IRS4), neither of which reaches program-level confidence. The pseudogene/olfactory receptor/ncRNA majority should be treated as a quality-control red flag. External statistical validation was not performed, and the GO/KEGG/STRING records are contextual annotations, not enrichment or replication evidence. The immediate priority is to determine whether the survival separation survives filtering for low-expression genes and adjustment for tumor purity, stage, and treatment—before any biological or translational interpretation is attempted.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=14, external claims checked=0, external mismatches=0, status=passed.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 56/100 selected items (partially returned; some queries failed); cbioportal 57/100 selected items (records returned); chembl 5/100 selected items (partially returned; some queries failed); civic 1/100 selected items (records returned); clinicaltrials 5/100 selected items (records returned); clinvar 29/100 selected items (records returned); ensembl 19/100 selected items (partially returned; some queries failed); europepmc 305 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 78/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 61/100 selected items (records returned); intact 10/100 selected items (partially returned; some queries failed); mygene 65/100 selected items (records returned); omnipath 6/100 selected items (records returned); opentargets 54/100 selected items (partially returned; some queries failed); pubmed 100 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 14/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 15/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 1/100 selected items (records returned); string 15/100 selected items (records returned); trrust 3/100 selected items (records returned)
